BRIEF—Rentschler appoints Mark Caswell as VP, Site Head for US Facility

Rentschler, a leading global contract development and manufacturing organization for biopharmaceuticals, has announced the appointment of Mark Caswell as vice president, site head.

He joined in July 2022 and is managing all operations at the company’s US facilities in Massachusetts, including the completion of the new Rentschler Biopharma Manufacturing Center adjacent to the existing site.

Mr Caswell has more than 25 years of experience in the biopharmaceutical industry. Prior to joining Rentschler, he worked at Lonza Biologicals as head of operations at the New Hampshire site. Before that, he worked at Sanofi Genzyme as director, global engineering and technology.

Frank Mathias, chief executive of Rentschler, said: "An important part of his responsibilities will be overseeing the completion of our state-of-the-art RBMC facility, the largest expansion in Rentschler's 150-year history. Under Mark’s leadership, I look forward to this new facility becoming client-ready and to ensuring we are well prepared to address our US clients’ growing needs to bring innovative therapies to patients."